Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1918

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice ; day:1 ; month:9 ; year:2016 ; pages:1-10
Clinical drug investigation ; (1.9.2016), 1-10

Creator: Lackey, Philip

Contributor: Mills, Anthony
Carpio, Felix
Hsu, Ricky
DeJesus, Edwin
Pierone, Gerald
Henegar, Cassidy
Fusco, Jennifer
Fusco, Gregory
Wohlfeiler, Mike
SpringerLink (Online service)

DOI: 10.1007/s40261-016-0456-1

URN: urn:nbn:de:1111-201609295658

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lackey, Philip
Mills, Anthony
Carpio, Felix
Hsu, Ricky
DeJesus, Edwin
Pierone, Gerald
Henegar, Cassidy
Fusco, Jennifer
Fusco, Gregory
Wohlfeiler, Mike
SpringerLink (Online service)

Other Objects (12)

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption

Related objects

Reset password